Immunocytometric Analysis of Oral Pemphigus vulgaris Patients after Treatment with Rituximab as Adjuvant

<b>Background:</b> B-cell depletion therapy was demonstrated to be a valid and safe alternative as an adjuvant in oral-pharyngeal pemphigus vulgaris (OPV) patients. We aimed to assess its effects on anti-desmoglein (Dsg) 1 and 3 and leukocytes subsets profile in these patients’ populatio...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Giulio Fortuna, Elena Calabria, Massimo Aria, Amerigo Giudice, Michele Davide Mignogna
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	rituximab remission oral pemphigus vulgaris disease severity OPV desmoglein Microbiology QR1-502
Acceso en línea:	https://doaj.org/article/25227ff5384d4019a68e59d6e2406d7f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:25227ff5384d4019a68e59d6e2406d7f
record_format	dspace
spelling	oai:doaj.org-article:25227ff5384d4019a68e59d6e2406d7f2021-11-25T16:53:07ZImmunocytometric Analysis of Oral Pemphigus vulgaris Patients after Treatment with Rituximab as Adjuvant10.3390/biom111116342218-273Xhttps://doaj.org/article/25227ff5384d4019a68e59d6e2406d7f2021-11-01T00:00:00Zhttps://www.mdpi.com/2218-273X/11/11/1634https://doaj.org/toc/2218-273X<b>Background:</b> B-cell depletion therapy was demonstrated to be a valid and safe alternative as an adjuvant in oral-pharyngeal pemphigus vulgaris (OPV) patients. We aimed to assess its effects on anti-desmoglein (Dsg) 1 and 3 and leukocytes subsets profile in these patients’ population. <b>Methods and Materials:</b> We evaluated the immunologic profile of 10 OPV patients treated with RTX as adjuvant by using the ELISA testing for anti-Dsg-1 and -3 titers and the immunophenotyping for B and T-cell lymphocyte subpopulations and compared them with the PDAI score for clinical remission. <b>Results:</b> A significant difference in medians between baseline, end of RTX therapy, and 6 months after RTX therapy was observed in Dsg-3 titer (<i>p</i> < 0.001), in the CD8 (<i>p</i> = 0.009), and CD20 counts (<i>p</i> < 0.001). Multiple comparisons after Bonferroni adjustment confirmed such significant differences mainly between baseline and the end of RTX therapy and baseline and 6 months after RTX therapy. Only the anti-Dsg-3 titer at the end of RTX therapy demonstrated a slight positive correlation with the PDAI score at baseline (<i>p</i> = 0.046, <i>r =</i> 0.652). <b>Conclusions:</b> B-cell depletion adjuvant therapy in OPV patients demonstrated a significant impact on anti-Dsg-3 titer and B and T-cell lymphocyte subpopulations profile.Giulio FortunaElena CalabriaMassimo AriaAmerigo GiudiceMichele Davide MignognaMDPI AGarticlerituximabremissionoral pemphigus vulgarisdisease severityOPVdesmogleinMicrobiologyQR1-502ENBiomolecules, Vol 11, Iss 1634, p 1634 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	rituximab remission oral pemphigus vulgaris disease severity OPV desmoglein Microbiology QR1-502
spellingShingle	rituximab remission oral pemphigus vulgaris disease severity OPV desmoglein Microbiology QR1-502 Giulio Fortuna Elena Calabria Massimo Aria Amerigo Giudice Michele Davide Mignogna Immunocytometric Analysis of Oral Pemphigus vulgaris Patients after Treatment with Rituximab as Adjuvant
description	<b>Background:</b> B-cell depletion therapy was demonstrated to be a valid and safe alternative as an adjuvant in oral-pharyngeal pemphigus vulgaris (OPV) patients. We aimed to assess its effects on anti-desmoglein (Dsg) 1 and 3 and leukocytes subsets profile in these patients’ population. <b>Methods and Materials:</b> We evaluated the immunologic profile of 10 OPV patients treated with RTX as adjuvant by using the ELISA testing for anti-Dsg-1 and -3 titers and the immunophenotyping for B and T-cell lymphocyte subpopulations and compared them with the PDAI score for clinical remission. <b>Results:</b> A significant difference in medians between baseline, end of RTX therapy, and 6 months after RTX therapy was observed in Dsg-3 titer (<i>p</i> < 0.001), in the CD8 (<i>p</i> = 0.009), and CD20 counts (<i>p</i> < 0.001). Multiple comparisons after Bonferroni adjustment confirmed such significant differences mainly between baseline and the end of RTX therapy and baseline and 6 months after RTX therapy. Only the anti-Dsg-3 titer at the end of RTX therapy demonstrated a slight positive correlation with the PDAI score at baseline (<i>p</i> = 0.046, <i>r =</i> 0.652). <b>Conclusions:</b> B-cell depletion adjuvant therapy in OPV patients demonstrated a significant impact on anti-Dsg-3 titer and B and T-cell lymphocyte subpopulations profile.
format	article
author	Giulio Fortuna Elena Calabria Massimo Aria Amerigo Giudice Michele Davide Mignogna
author_facet	Giulio Fortuna Elena Calabria Massimo Aria Amerigo Giudice Michele Davide Mignogna
author_sort	Giulio Fortuna
title	Immunocytometric Analysis of Oral Pemphigus vulgaris Patients after Treatment with Rituximab as Adjuvant
title_short	Immunocytometric Analysis of Oral Pemphigus vulgaris Patients after Treatment with Rituximab as Adjuvant
title_full	Immunocytometric Analysis of Oral Pemphigus vulgaris Patients after Treatment with Rituximab as Adjuvant
title_fullStr	Immunocytometric Analysis of Oral Pemphigus vulgaris Patients after Treatment with Rituximab as Adjuvant
title_full_unstemmed	Immunocytometric Analysis of Oral Pemphigus vulgaris Patients after Treatment with Rituximab as Adjuvant
title_sort	immunocytometric analysis of oral pemphigus vulgaris patients after treatment with rituximab as adjuvant
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/25227ff5384d4019a68e59d6e2406d7f
work_keys_str_mv	AT giuliofortuna immunocytometricanalysisoforalpemphigusvulgarispatientsaftertreatmentwithrituximabasadjuvant AT elenacalabria immunocytometricanalysisoforalpemphigusvulgarispatientsaftertreatmentwithrituximabasadjuvant AT massimoaria immunocytometricanalysisoforalpemphigusvulgarispatientsaftertreatmentwithrituximabasadjuvant AT amerigogiudice immunocytometricanalysisoforalpemphigusvulgarispatientsaftertreatmentwithrituximabasadjuvant AT micheledavidemignogna immunocytometricanalysisoforalpemphigusvulgarispatientsaftertreatmentwithrituximabasadjuvant
_version_	1718412881877270528

Immunocytometric Analysis of Oral Pemphigus vulgaris Patients after Treatment with Rituximab as Adjuvant

Ejemplares similares